New arthritis drug given green light

New arthritis drug given green light

Hundreds of thousands of rheumatoid arthritis (RA) sufferers could benefit from a new treatment after the drugs spending watchdog changed its mind about prescribing it on the NHS.

By Stephen Adams, Medical Correspondent 6:30AM BST 13 May 2011

Those with moderate to severe RA will now be able to get Simponi, the brand name of the drug golimumab, in some situations where similar treatments have not worked.

Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society (NRAS), described it as “excellent news”.

“It is vital that we have options when it comes to biologic therapies as people react differently to drugs even within the same class,” she said.

Simponi is what is known as a tumour necrosis factor inhibitor, or anti-TNF, drug.

These work by blocking the action of TNF, a naturally occurring chemical, which plays an important role in triggering inflammation and tissue damage.


Others in this class have already been given the green light by the National Institute for Health and Clinical Excellence (Nice), including Humira, Endrel, Remicade and Cimzia. However, sometimes they stop working in patients.

Last October, Nice turned down Simponi but, in final draft guidance published today (FRI), the body has changed its mind. A Nice spokesman said the decision was due to new clinical and cost evidence put forward by the manufacturer, Merck. He emphasised that final guidance was still to come.

Almost 700,000 people in Britain suffer from RA, making it the second most common form of rheumatic disease after osteoarthritis. Of those, some 400,000 suffer from moderate or severe symptoms.

Three quarters are diagnosed while still of working age. More than one in four of them have to give up employment within a year of diagnosis. The NRAS has calculated it costs the economy £8 billion a year due to lost productivity.

Exactly how RA is treated depends on its severity: those with mild arthritis are often advised to start by taking paracetamol, and move on to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs).

Exercise is also essential to keeping joints mobile.

However, the disease tends to be progressive. As it gets worse more powerful medicines including disease modifying anti-rheumatic drugs (DMARDs) and anti-TNFs come into play.

Neil Betteridge, chief executive of the charity Arthritis Care, welcomed Nice’s change of tune.

He said: “Rheumatoid arthritis is an awful disease affecting people of all ages which clinicians often compare with having cancer of the joints.

“Unless treated and managed effectively it invariably leads to great pain and can render people immobile and unable to work. Having another treatment option available, therefore, is terrific.”

One benefit of Simponi is that patients can self-inject the drug, and need only do so once a month.

However, it “can lower your ability to fight infections”, warns Merck, and there have been reports of “serious infections” including tuberculosis, some of which have been fatal.

Peter Taylor, professor of experimental rheumatology at Imperial College, London, said: “I am excited by the launch of ‘Simponi’ as it represents a valuable additional choice for the treatment of these debilitating rheumatoid conditions, and any new therapy that improves quality of life for patients is most welcome.

“Early and effective management is important in reducing disease progression and the extensive joint damage associated with it, but it’s also important for patients to have a say in the choice of treatment they receive.”

One Response to New arthritis drug given green light

  1. Jan Barber-Maltby says:

    This is fantastic news.
    I am an osteo/rheumatoid arthritic sufferer, and I had to give up full time in employment in the catering industry in 2006. I take at present Leflunomide and at regular intervals have to have injections of Depomedrone to stay on top of the inflammation of the joints, also corticosteroids in my hip joints to ease the pain of walking.
    A new therapy will certainly help the thousands that suffer with this debilitating disease, even so more research is required into Arthritis.

Leave a Reply

Your email address will not be published. Required fields are marked *

 characters available

Notify me of followup comments via e-mail. You can also subscribe without commenting.